Valuation: IMPACT Therapeutics, Inc

Market Cap 3.14B 3.68B 469M 417M 386M 351M 663M 44.48B 674M 4.64B 1.82B 23.21B 1.76B 1.72B 73.99B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 2.32B 2.72B 347M 308M 286M 260M 490M 32.9B 498M 3.43B 1.35B 17.17B 1.3B 1.27B 54.72B EV / Sales 2026 *
8.76x
EV / Sales 2027 * 3.38x
Free-Float
53.09%
Yield 2026 *
-
Yield 2027 * -
1 day+0.54%
1 week+2.68%
Current month-7.46%
1 month+15.53%
3 months-17.07%
1 week 11.86
Extreme 11.86
14.5
1 month 11.3
Extreme 11.3
20.56
Current year 10.31
Extreme 10.31
47.98
1 year 10.31
Extreme 10.31
47.98
3 years 10.31
Extreme 10.31
47.98
5 years 10.31
Extreme 10.31
47.98
10 years 10.31
Extreme 10.31
47.98
Manager TitleAgeSince
Chief Executive Officer 69 01/06/2014
Director of Finance/CFO 51 01/05/2024
Chief Tech/Sci/R&D Officer 44 01/01/2025
Director TitleAgeSince
Director/Board Member 69 01/06/2014
Director/Board Member 69 01/06/2014
Director/Board Member 44 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%+2.68% - - 469M
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.61%-1.23%+43.33%+85.71% 37.24B
Weighted average by Cap. -2.29%-1.20%+43.56%+88.58%

Financials

2026 *2027 *
Net sales 265M 311M 39.57M 35.18M 32.6M 29.66M 55.98M 3.76B 56.87M 392M 154M 1.96B 149M 145M 6.25B 630M 738M 94.1M 83.64M 77.53M 70.54M 133M 8.93B 135M 932M 365M 4.66B 353M 346M 14.86B
Net income - -
Net Debt -816M -958M -122M -108M -101M -91.46M -173M -11.58B -175M -1.21B -474M -6.04B -458M -448M -19.26B -1.01B -1.18B -150M -134M -124M -113M -213M -14.27B -216M -1.49B -584M -7.44B -564M -552M -23.73B
Projected Income Statement - Annual - IMPACT Therapeutics, Inc
Logo IMPACT Therapeutics, Inc
IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.
Employees
-
Date Price Change Volume
16/10/26 HK$13.02 +0.54% 6,178,600
15/10/26 HK$12.95 -2.78% 1,961,000
14/10/26 HK$13.32 +8.47% 4,958,800
13/10/26 HK$12.28 -0.73% 1,563,400
12/10/26 HK$12.37 -2.44% 2,003,400
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
11.10CNY
Average target price
27.28CNY
Spread / Average Target
+145.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IMPACT Therapeutics, Inc
  1. Stock Market
  2. Stocks
  3. 7630 Stock